X4 Pharmaceuticals Inc — Cash Flow (NASDAQ:XFOR) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -58.82 M-70.91 M-77.1 M-96.51 M-130.9 M-85.62 M -85.62 M Cash from investing activities -1.36 M-615 K-103 K-14.88 M66.99 M8.15 M 8.15 M Cash from financing activities 12.39 M74.25 M117.23 M88.52 M20.29 M238.63 M 238.63 M Free cash flow -60.18 M-71.52 M-77.2 M-96.57 M-138.23 M-85.62 M -85.62 M

News

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

EMA panel backs mavorixafor for ultra-rare WHIM syndrome

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?

Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday - Agios Pharmaceuticals (NASDAQ:AGIO), Bioage Labs (NASDAQ:BIOA)

X4 Pharmaceuticals stock rating raised to Buy by Stifel, price target up to $10